Product Information

Registration Status: Active

PINETARSOL SOLUTION 2.3% W/W is approved to be sold in Singapore with effective from 1990-03-20. It is marketed by EGO PHARMACEUTICALS (SINGAPORE) PTE LTD, with the registration number of SIN04022P.

This product contains Tar 2.3% w/w in the form of SOLUTION. It is approved for ORAL use.

This product is manufactured by EGO PHARMACEUTICALS PTY LTD in AUSTRALIA.

It is an Over-the-counter Medicine that can be freely obtained from any retailer



Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma.


Used orally for the treatment of skin manifestations of cutaneous T-cell lymphoma (CTCL) in patients who are refractory to at least one prior systemic therapy. Also used topically for the treatment of skin lesions in early (stage IA and IB) CTCL in patients who experience refractory or persistent disease with the use of other therapies or are intolerant of other therapies.

Mechanism of Action

Bexarotene selectively binds with and activates retinoid X receptor subtypes. There are three subtypes in total: RXRα, RXRβ, RXRγ. The exact mechanism of action of bexarotene in the treatment of CTCL is unknown but the drug has activity in all clinical stages of CTCL.

Active Ingredient/Synonyms

4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid | 4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid | Bexaroten | Bexarotène | Bexarotene | Bexaroteno | Bexarotenum | P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid | p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid | Targretyn | Targrexin | Bexarotene |

Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.


  1. Health Science Authority of Singapore - Reclassified POM
  2. Drugbank